Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avanos Medical (AVNS) Net Income towards Common Stockholders (2016 - 2024)

Avanos Medical's Net Income towards Common Stockholders history spans 10 years, with the latest figure at -$1.6 million for Q3 2024.

  • For Q3 2024, Net Income towards Common Stockholders fell 131.37% year-over-year to -$1.6 million; the TTM value through Dec 2024 reached -$5.5 million, up 89.4%, while the annual FY2023 figure was -$51.9 million, 278.97% down from the prior year.
  • Net Income towards Common Stockholders for Q3 2024 was -$1.6 million at Avanos Medical, up from -$2.5 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $37.8 million in Q2 2021 and bottomed at -$63.8 million in Q2 2023.
  • The 5-year median for Net Income towards Common Stockholders is -$500000.0 (2023), against an average of -$4.6 million.
  • The largest annual shift saw Net Income towards Common Stockholders skyrocketed 1360.0% in 2021 before it tumbled 565.69% in 2023.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$49.0 million in 2020, then surged by 47.55% to -$25.7 million in 2021, then soared by 128.02% to $7.2 million in 2022, then tumbled by 106.94% to -$500000.0 in 2023, then crashed by 220.0% to -$1.6 million in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Net Income towards Common Stockholders are -$1.6 million (Q3 2024), -$2.5 million (Q2 2024), and -$1.4 million (Q1 2024).